Results from use of Cantargia’s antibodies against IL1RAP published in scientific journal Blood
An article by Cantargia AB’s (“Cantargia”) founder and Board member Dr Thoas Fioretos and founder Dr Marcus Järås has been published in the respected scientific journal Blood. In the article, Cantargia’s antibodies are utilized in the treatment of chronic myeloid leukemia (CML) in preclinical models.The article describes studies in preclinical models of chronic myeloid leukemia. The results show a positive effect in these disease models from the use of antibodies against IL1RAP. In particular, a clear treatment effect was evident in “PDX” models, where tumour cells derived directly from